corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 12463

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: news

McKee S.
Amgen hit with Enbrel subpoena
PharmaTimes 2008 Jan 18
http://www.pharmatimes.com/WorldNews/article.aspx?id=12669&src=EWorldNews


Full text:

US biotechnology giant Amgen has reportedly been served with a subpoena for information regarding its anti-inflammatory blockbuster Enbrel, following accusations that the firm promoted the drug for unlicensed uses.

Documents going back as far as 2002 relating to the marketing and sale of Enbrel (etanercept) have been requested, and a spokeswoman for Amgen told Reuters that the company will “cooperate fully with the New Jersey attorney general in this investigation.”

There were also allegations by two of the company’s sales representatives that they had been pushed by the firm into getting hold of patient data to sift out those suffering from psoriasis who could be suited to treatment with the drug, thereby violating patient confidentiality laws, reports the New York Times.

The news came shortly after Amgen and Wyeth reported results from a Phase III study showing that Enbrel was able to significantly improve the symptoms of moderate-to-severe plaque psoriasis in children and adolescents.

The results, which will be published in the New England Journal of Medicine, will support the company’s application to market the drug in paediatric psoriasis. If successful, Enbrel could be the first biologic and systemic therapy specifically approved for use in this age group, the company said.

Enbrel is a fully-human soluble tumour necrosis factor receptor, first approved in 1998 for moderate-to-severe rheumatoid arthritis and since used in nearly 500,000 patients around the globe. The drug generated sales of $821 million in the third quarter of 2007, marking growth of 16% over the year-earlier period.

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend








Far too large a section of the treatment of disease is to-day controlled by the big manufacturing pharmacists, who have enslaved us in a plausible pseudo-science...
The blind faith which some men have in medicines illustrates too often the greatest of all human capacities - the capacity for self deception...
Some one will say, Is this all your science has to tell us? Is this the outcome of decades of good clinical work, of patient study of the disease, of anxious trial in such good faith of so many drugs? Give us back the childlike trust of the fathers in antimony and in the lancet rather than this cold nihilism. Not at all! Let us accept the truth, however unpleasant it may be, and with the death rate staring us in the face, let us not be deceived with vain fancies...
we need a stern, iconoclastic spirit which leads, not to nihilism, but to an active skepticism - not the passive skepticism, born of despair, but the active skepticism born of a knowledge that recognizes its limitations and knows full well that only in this attitude of mind can true progress be made.
- William Osler 1909